Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928776 | 0.92 | SLC9A1 (0.34) | SLC9A1ACHE | |
| SCHEMBL7916778 | 0.83 | SLC9A1 (0.33) | SLC9A1ACHE | |
| SCHEMBL927447 | 0.83 | SLC9A1 (0.39) | SLC9A1ACHE | |
| SCHEMBL7911358 | 0.82 | SLC9A1 (0.38) | SLC9A1ACHE | |
| SCHEMBL7912931 | 0.75 | SLC9A1 (0.59) | SLC9A1ACHE | |
| SCHEMBL7916794 | 0.74 | SLC9A1 (0.61) | SLC9A1ACHE | |
| SCHEMBL927184 | 0.74 | SLC9A1 (0.61) | SLC9A1ACHE | |
| SCHEMBL7916773 | 0.74 | SLC9A1 (0.37) | SLC9A1ACHE | |
| SCHEMBL926206 | 0.73 | SLC9A1 (0.33) | SLC9A1 | |
| SCHEMBL7910322 | 0.72 | SLC9A1 (0.43) | SLC9A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875625-B2 | 3-guanidinocarbonyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylmethyl hydrogen sulfate, inhibitory effect on an Na+/H+ exchanger; | TOA EIYO LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20090012114-A1 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same | TOA EIYO LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1849774-A1 | CYCLOHEPTA(b)PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | TOA EIYO LTD. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012114-A1 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same | SLC10A6, SLC26A3, SLC9A3 | SLC9A1 5/4885ACHE 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.